


**CLEAN VERSION OF AMENDED CLAIMS**

1. (Currently amended) A composition for the treatment of proliferative disorders, comprising an antineoplastic agent and a compound having the formula:



and pharmaceutically acceptable salts thereof;  
wherein

R is a member selected from the group consisting of hydrogen and substituted or unsubstituted (C<sub>1</sub>-C<sub>10</sub>)alkyl; and


Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

8. (Currently amended) A composition in accordance with claim 7, wherein said substituents on said phenyl group are selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, -OPO<sub>3</sub>H<sub>2</sub>, -OC(O)R', -NR'R'', -CO<sub>2</sub>R', -CONR'R'', -C(O)R', -OC(O)NR'R'', -NR''C(O)R', -NR''C(O)<sub>2</sub>R', -NR'-C(O)NR''R''', perfluoro(C<sub>1</sub>-C<sub>4</sub>)alkoxy, and perfluoro(C<sub>1</sub>-C<sub>4</sub>)alkyl, wherein R', R'' and R''' is each independently hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl.

17. (Currently amended) A method for the treatment of a proliferative disorder, comprising administering to a subject in need of such treatment:

i) a first amount of an antineoplastic agent; and

4           ii) a second amount of a compound of formula:



5

6

and pharmaceutically acceptable salts thereof; wherein

7

R is a member selected from the group consisting of hydrogen and  
substituted or unsubstituted (C<sub>1</sub>-C<sub>10</sub>)alkyl; and

8

9

Ar is a member selected from the group consisting of substituted or  
unsubstituted aryl and substituted or unsubstituted heteroaryl;

10

11

wherein said first amount and said second amount, in combination, are effective to  
treat said proliferative disorder.

12